Patents Represented by Attorney Algis Anilionis

Find this attorney in the Justia Lawyer Directory

  • Substituted pyridoxazines
    Patent number: 7960377
    Abstract: The invention provides compounds having the structure of formula I, and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3 and R4 are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: June 14, 2011
    Assignee: Cara Therapeutics, Inc.
    Inventors: Jason S. Newcom, Stephen J. O'Connor, Gary R. Gustafson
  • Benzo-fused heterocycles
    Patent number: 7960376
    Abstract: The present invention provides benzo-fused heterocyclic compounds having the structure of formula I, as well as prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof. The compounds directly or indirectly modulate the activity of one or more cannabinoid receptors and can be incorporated into pharmaceutical preparations that are useful for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: June 14, 2011
    Assignee: Cara Therapeutics, Inc.
    Inventors: Jason S. Newcom, Carla M. Gauss, Gary R. Gustafson
  • Bicyclic pyrazolo-heterocycles
    Patent number: 7741350
    Abstract: The present invention provides substituted pyrazolo-heterocycles having the general structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: June 22, 2010
    Assignee: Cara Therapeutics, Inc.
    Inventor: Robert Zhiyong Luo
  • Synthetic peptide amides and dimeric forms thereof
    Patent number: 7713937
    Abstract: The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: wherein Xaa is a D-amino acid and G is selected from the following three groups: The compounds are useful in the prophylaxis and treatment of pain, pruritis and inflammation associated with a variety of diseases and conditions.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 11, 2010
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
  • Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain
    Patent number: 7517874
    Abstract: The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: April 14, 2009
    Assignee: Cara Therapeutics, Inc.
    Inventors: R. Paul Beckett, Richard Foster, Christelle Henault, Janet L. Ralbovsky, Carla M. Gauss, Gary G. Gustafson, Zhiyong Luo, Ann-Marie Campbell, Tatiana E. Shelekhin